Accredo: Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

SOUTH SAN FRANCISCO, Calif., May 13, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has executed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. Titan expects the majority of Probuphine sales in the United States to be...